Abstract
In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
Advances in Therapy Open Access 07 October 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Jemal, A. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).
Oh, W. K. & Schurko, B. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clin. Pract. Oncol. 5, 506–507 (2008).
Patel, P. H. & Kockler, D. R. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42, 91–98 (2008).
Gilboa, E. The promise of cancer vaccines. Nature Rev. Cancer 4, 401–411 (2004).
US Food and Drug Administration. FDA labelling information — Provenge. FDA website [online], (2010).
Small, E. J. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894–3903 (2000).
Burch, P. A. et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175–2182 (2000).
Small, E. J. et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094 (2006).
Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1488–1490 (2004).
Beer, T. M. et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J. Clin. Oncol. 25, 18S (2007).
Kelly, W. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J. Clin. Oncol. 28, 344s (2010).
IMS MIDAS (2009).
Reams, A. & Andrews, M. J. Biotechnology equity research report. Wells Fargo Securities (19 May 2010).
Kasimov, C., Ashiya M. & Jay, K. Equity research report. JP Morgan North America (11 May 2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Higano, C., Small, E., Schellhammer, P. et al. Sipuleucel-T. Nat Rev Drug Discov 9, 513–514 (2010). https://doi.org/10.1038/nrd3220
Issue Date:
DOI: https://doi.org/10.1038/nrd3220
This article is cited by
-
Targeting drugs to tumours using cell membrane-coated nanoparticles
Nature Reviews Clinical Oncology (2023)
-
A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
Advances in Therapy (2020)
-
Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens
Acta Neuropathologica (2017)